Biomarin Pharmaceutical Inc (BMRN)

Financial leverage ratio

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Total assets	US$ in thousands	6,872,670	6,841,600	6,758,160	6,563,170	6,433,700	6,375,070	6,264,040	6,145,840	6,062,710	6,004,770	5,977,480	5,898,500	5,805,050	5,848,020	6,158,090	5,302,110	4,722,840	4,690,040	4,558,130	4,393,380
Total stockholders’ equity	US$ in thousands	5,073,820	4,951,550	4,896,900	4,782,830	4,659,040	4,603,160	4,568,510	4,499,740	4,386,240	4,265,670	4,261,080	4,236,500	4,162,010	4,100,930	4,053,890	3,236,680	3,239,960	3,122,380	3,074,400	2,960,950
Financial leverage ratio		1.35	1.38	1.38	1.37	1.38	1.38	1.37	1.37	1.38	1.41	1.40	1.39	1.39	1.43	1.52	1.64	1.46	1.50	1.48	1.48

March 31, 2024 calculation

Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $6,872,670K ÷ $5,073,820K
= 1.35

The financial leverage ratio of Biomarin Pharmaceutical Inc has shown some fluctuations over the past several quarters. The ratio has generally ranged between 1.35 to 1.52, indicating that the company has been utilizing a moderate level of financial leverage.

It is important to note that a financial leverage ratio above 1 indicates that the company has more debt than equity in its capital structure. A higher ratio implies higher financial risk due to the increased reliance on debt financing.

Despite some variability in the ratio over time, Biomarin Pharmaceutical Inc has maintained a relatively stable level of financial leverage, with the ratio hovering around 1.38 on average. Investors and analysts may want to closely monitor the trend in the financial leverage ratio to assess the company's ability to manage its debt levels effectively and sustain its financial health in the long run.